Mesenchymal Stem Cells and Uses Therefor

Abstract

Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.

1 . A method of treating an inflammatory response in an animal having inflammatory bowel disease, comprising the step of:
 administering to the animal allogeneic, isolated mesenchymal stem cells in an amount effective to treat the inflammatory response in the animal,   wherein the mesenchymal stem cells limit or reduce intestinal inflammation.   
     
     
         2 . The method of  claim 1 , wherein the animal is a human. 
     
     
         3 . The method of  claim 1 , wherein the mesenchymal stem cells are administered in an amount of from about 1×10 5  cells/kg to about 1×10 7  cells/kg. 
     
     
         4 . The method of  claim 3 , wherein the mesenchymal stem cells are administered in an amount of from about 1×10 6  cells/kg to about 5×10 6  cells/kg. 
     
     
         5 . The method of  claim 1 , wherein the mesenchymal stem cells are administered systemically. 
     
     
         6 . The method of  claim 5 , wherein the mesenchymal stem cells are administered intravenously. 
     
     
         7 . The method of  claim 5 , wherein the mesenchymal stem cells are administered intraarterially. 
     
     
         8 . The method of  claim 5 , wherein the mesenchymal stem cells are administered intraperitoneally. 
     
     
         9 . The method of  claim 1 , wherein the mesenchymal stem cells express one or more cell surface markers selected from the group consisting of CD73, CD105, and CD166. 
     
     
         10 . The method of  claim 1 , wherein the mesenchymal stem cells bind to an antibody selected from the group consisting of an antibody produced from hybridoma cell line SH2, ATCC accession number HB 10743, an antibody produced from hybridoma cell line SH3, ATCC accession number HB 10744, and an antibody produced from hybridoma cell line SH4, ATCC accession number HB 10745. 
     
     
         11 . The method of  claim 1 , wherein the mesenchymal stem cells are administered in conjunction with an acceptable pharmaceutical carrier. 
     
     
         12 . The method of  claim 11 , wherein the acceptable pharmaceutical carrier is a pharmaceutically acceptable liquid medium for injection. 
     
     
         13 . The method of  claim 1 , wherein the mesenchymal stem cells are administered as a suspension of cells. 
     
     
         14 . The method of  claim 13 , wherein at least about 95% of the cells in the suspension express one or more cell surface markers selected from the group consisting of CD73, CD105, and CD166. 
     
     
         15 . The method of  claim 13 , wherein at least about 98% of the cells in the suspension express one or more cell surface markers selected from the group consisting of CD73, CD105, and CD166. 
     
     
         16 . A method of treating intestinal inflammation associated with inflammatory bowel disease in an animal, comprising the step of:
 systemically administering to the animal a suspension of cells in an amount effective to treat the intestinal inflammation;   wherein at least about 95% of the cells are allogeneic mesenchymal stem cells.   
     
     
         17 . The method of  claim 16 , wherein the animal is a human. 
     
     
         18 . The method of  claim 16 , wherein the suspension is administered in an amount of from about 1×10 5  cells/kg to about 1×10 7  cells/kg. 
     
     
         19 . The method of  claim 16 , wherein the suspension is administered in an amount of from about 1×10 6  cells/kg to about 5×10 6  cells/kg. 
     
     
         20 . The method of  claim 16 , wherein the suspension is administered intravenously. 
     
     
         21 . The method of  claim 16 , wherein the suspension is administered intraarterially. 
     
     
         22 . The method of  claim 16 , wherein the mesenchymal stem cells express one or more cell surface markers selected from the group consisting of CD73, CD105, and CD166. 
     
     
         23 . The method of  claim 16 , wherein the mesenchymal stem cells bind to an antibody selected from the group consisting of an antibody produced from hybridoma cell line SH2, ATCC accession number HB 10743, an antibody produced from hybridoma cell line SH3, ATCC accession number HB 10744, and an antibody produced from hybridoma cell line SH4, ATCC accession number HB 10745. 
     
     
         24 . The method of  claim 16 , wherein the suspension is further comprises an acceptable pharmaceutical carrier. 
     
     
         25 . The method of  claim 24 , wherein the acceptable pharmaceutical carrier is a pharmaceutically acceptable liquid medium for injection. 
     
     
         26 . The method of  claim 16 , wherein at least about 98% of the cells in the suspension are allogeneic mesenchymal stem cells.